July 15, 2017 Affymax’s database lock achievement in Phase 3 Hematide trial triggers $30M milestone payment from Takeda Affymax, Inc. The payments had been triggered by the accomplishment of database lock in the EMERALD and PEARL Stage 3 clinical trials, which evaluated Hematide to treat anemia in persistent renal failure sufferers. Affymax and Takeda are collaborating on the advancement of Hematide and can co-commercialize the product in the United States upon authorization. Takeda holds a special license to develop and commercialize Hematide beyond your United States, including Japan.This implies though they seldom occur even, they each raise the probability a person could have an autism spectrum disorder . CBS Evening News Is there a connection between Asperger’s and violent behavior? CBS News medical correspondent Dr. Jon LaPook spoke with Scott Pelley on Asperger’s syndrome – the disorder Adam Lanza, the gunman in the Conn. S. ‘Many of these gene variants may serve as beneficial predictive markers,’ the study’s corresponding writer Dr. Hakon Hakonarson, director of the Center for Applied Genomics at The Children’s Hospital of Philadelphia, stated in a press release. ‘If so, they could become component of a clinical test that will help evaluate whether a child comes with an autism spectrum disorder.’ According to the Centers for Disease Prevention and Control, one in 88 children in the U.S.